Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists
Eli Lilly is acquiring Centessa Pharmaceuticals to gain access to orexin receptor 2 (OX2R) agonist programs, expanding its neuroscience pipeline beyond GLP-1. The deal positions LLY to compete in sleep disorders and narcolepsy, adding a potential multi-billion-dollar category to its already high-growth platform.
What happened
Eli Lilly is acquiring Centessa Pharmaceuticals to gain access to orexin receptor 2 (OX2R) agonist programs, expanding its neuroscience pipeline beyond GLP-1.
The read · Jun 26
LLY's Centessa acquisition adds a novel OX2R pipeline to an already high-growth platform — the question is whether the deal price and clinical stage justify the capital outlay or dilute near-term returns.
Wrong if
A high acquisition premium with only early-stage clinical data would signal capital misallocation; any Phase 2 setback for the OX2R program post-close would be a direct negative for the rationale of the deal.
CoverageSource: Yahoo Finance · Published here FRI, JUN 26 · 4:06 AM ET · the only report in this recordHow this is decided →
The chart · LLYTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Eli Lilly has agreed to acquire Centessa Pharmaceuticals, a UK-based clinical-stage biotech, in a move that brings OX2R agonist assets into Lilly's neuroscience pipeline. Orexin receptor 2 agonists are a mechanistically novel class targeting narcolepsy and excessive daytime sleepiness — a space where Takeda's solriamfetol and Jazz Pharmaceuticals' Xywav compete but where no oral OX2R agonist has yet reached the market. No deal price has been publicly confirmed in this initial headline.
Lilly arrives at this deal off a period of exceptional top-line momentum: FY2025 revenues reached $65.2B, up 44.7% year-over-year, driven heavily by tirzepatide (Mounjaro/Zepbound). Net margin stood at 31.7% and diluted EPS came in at $22.95, giving Lilly the financial firepower to pursue bolt-on acquisitions without straining its balance sheet. Adding Centessa diversifies Lilly away from near-total dependence on GLP-1 revenues.
The strategic rationale is clear: OX2R agonists represent one of the most watched emerging CNS mechanisms, with TAM estimates in narcolepsy alone running into several billion dollars. Competitors including Takeda and Jazz have CNS exposure, but a successful oral OX2R agonist would be a first-in-class product. Centessa's lead asset, previously called ORX750, was in early-to-mid clinical development — de-risked enough to be attractive but early enough that Lilly could shape the clinical program.
The key unknowns are deal price, milestone structure, and how far Centessa's OX2R data actually extend. If the acquisition comes at a rich premium to Centessa's last traded value, markets may react negatively to capital deployment. If the price is reasonable and Phase 2 data are compelling, the deal could be viewed as a disciplined, high-optionality add-on for a company with the cash flow to absorb execution risk.
What to watch: official deal terms and any disclosed clinical data package; analyst reaction to the strategic fit versus GLP-1 concentration risk; and whether Lilly guides for any revenue contribution timeline from the neuroscience pipeline in upcoming earnings calls.
The read, in fullWhy it matters
Lilly's balance sheet ($65.2B revenue, 31.7% net margin) can absorb this acquisition comfortably, and OX2R agonists represent a genuine first-in-class CNS opportunity. However, without disclosed deal price, premium paid over Centessa's market cap, or Phase 2 efficacy data, it is impossible to size a directional trade with honest conviction — the risk/reward is undefined.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUN 26 on
Next · what would move this
Until deal terms and clinical stage are disclosed. Follow to be told when one lands.
▲ The case it holds
Lilly's 44.7% revenue growth and 31.7% net margin give it the financial capacity to absorb an early-stage CNS bet while OX2R agonists, if successful, represent a first-in-class oral treatment for narcolepsy with multi-billion-dollar TAM potential entirely additive to the GLP-1 franchise.
▼ The case it breaks
Without disclosed deal terms or confirmed Phase 2 data, investors cannot assess whether Lilly is overpaying for a pre-commercial asset in a mechanism that has seen prior clinical failures, and the GLP-1 franchise already commands a premium multiple that leaves little margin for capital-allocation missteps.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →
This page is kept as it was written on Jun 26. Later coverage joins it only when the company and catalyst evidence match, and what the stock did is shown from licensed end-of-day closes — never re-graded, never backdated. The judgment is yours.